<DOC>
	<DOCNO>NCT00858117</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , alemtuzumab rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Giving alemtuzumab together rituximab may kill cancer cell . PURPOSE : This phase II trial study side effect give alemtuzumab together rituximab see well work treat patient previously untreated B-cell chronic lymphocytic leukemia .</brief_summary>
	<brief_title>A Phase II Trial Alemtuzumab Rituximab Patients With Previously Untreated CLL</brief_title>
	<detailed_description>OBJECTIVES : - To determine response rate patient previously untreated B-cell chronic lymphocytic leukemia treat alemtuzumab rituximab . - To evaluate toxicity alemtuzumab rituximab patient . OUTLINE : Patients receive alemtuzumab subcutaneously day 1 , 3 , 5 week 1-18 rituximab IV day 1 week 3 , 5 , 7 , 9 , 11 , 13 , 15 , 17 absence disease progression unacceptable toxicity . Peripheral blood bone marrow sample collect periodically laboratory biomarker study . Samples analyze surface marker ( e.g. , CD3 , CD4 , CD8 , CD10 , CD19 , CD20 , CD25 , CD38 , CD52 , Zap-70 ) IgVH PCR , flow cytometry , FISH . Samples also analyze alemtuzumab anti-alemtuzumab antibody level flow cytometry . After completion study treatment , patient follow periodically 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis Bcell chronic lymphocytic leukemia ( CLL ) * , define follow criterion : Peripheral blood absolute lymphocyte count &gt; 5,000/mm³ Small moderatesize lymphocytes &lt; 55 % prolymphocytes , atypical lymphocyte , lymphoblast Phenotypically characterize BCLL express CD20 CD52 , define follow : Predominant population cell share Bcell antigens CD5 absence panTcell marker ( e.g. , CD3 , CD2 ) Bcell express either lambda kappa light chain Surface immunoglobulin lowcell surface density expression NOTE : *Presence splenomegaly , hepatomegaly , lymphadenopathy require diagnosis CLL Requires therapy , indicate ≥ 1 follow criterion : Unintentional weight loss &gt; 10 % within past 6 month Extreme fatigue ( i.e. , ECOG performance status 2 ) Fevers &gt; 100.5°F 2 week without evidence infection Night sweat without evidence infection Evidence progressive marrow failure manifest development worsen anemia ( hemoglobin &lt; 10 g/dL ) and/or thrombocytopenia ( platelet count &lt; 100,000/mm³ ) Massive ( i.e. , &gt; 6 cm leave costal margin ) progressive splenomegaly Massive nodes/clusters ( &gt; 5 cm ) , progressive symptomatic adenopathy , adenopathy result endorgan damage Progressive lymphocytosis increase &gt; 50 % 2 month anticipate doubling time &lt; 6 month Marked hypogammaglobulinemia development monoclonal protein absence criterion active disease sufficient eligibility PATIENT CHARACTERISTICS : ECOG performance status 02 ANC ≥ 1,000/mm³* Platelet count ≥ 50,000/mm³* Hemoglobin ≥ 10 g/dL* Serum creatinine ≤ 2.0 mg/dL OR creatinine clearance &gt; 40 mL/min Bilirubin &lt; 2 mg/dL AST ALT ≤ 2 time normal ( unless secondary tumor infiltration/lymphadenopathy ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month completion study treatment No active autoimmune anemia thrombocytopenia No active infection require oral intravenous antibiotic No second malignancy , basal cell carcinoma skin situ carcinoma cervix , unless curatively treat ≥ 2 year ago NOTE : *If cytopenia due degree bone marrow involvement , patient may eligible discretion principal investigator . PRIOR CONCURRENT THERAPY : Prior corticosteroid therapy allow No prior cytotoxic therapy ( corticosteroid )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
</DOC>